In the realm of advanced pharmaceutical treatments, understanding the molecules driving innovation is crucial for industry professionals. Pralatrexate, chemically known as 10-Propargyl-10-deazaaminopterin and carrying the CAS number 146464-95-1, has emerged as a significant therapeutic agent, particularly in the fight against certain hematological cancers. As a leading manufacturer and supplier of fine chemicals, we provide insights into this important compound, its mechanisms, and how to procure it effectively.

Pralatrexate belongs to a class of drugs known as antifolates. Its primary mode of action is through the potent inhibition of dihydrofolate reductase (DHFR), an enzyme critical for the synthesis of tetrahydrofolate. Tetrahydrofolate is a vital coenzyme in the de novo synthesis of purines and thymidylate, which are the building blocks of DNA. By blocking DHFR, Pralatrexate effectively disrupts DNA replication and repair, leading to cell cycle arrest and apoptosis, especially in rapidly proliferating cancer cells.

Mechanism of Action and Superiority:

What sets Pralatrexate apart from some other antifolates is its specific transport and intracellular metabolism. It is efficiently transported into cells via the reduced folate carrier (RFC) and subsequently undergoes polyglutamation catalyzed by folylpolyglutamate synthetase (FPGS). This process increases intracellular retention and enhances the inhibition of DHFR and other folate-dependent enzymes. Studies have shown that Pralatrexate exhibits significantly higher cellular uptake and polyglutamation compared to methotrexate, contributing to its enhanced potency and efficacy in certain cancer models.

Clinical Efficacy in PTCL:

The clinical application of Pralatrexate has been most prominent in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of non-Hodgkin’s lymphoma. Its approval for this indication marked a significant advancement in treatment options for patients who have not responded to standard therapies. The drug has demonstrated marked, complete, and durable remissions in a diversity of chemotherapy-refractory cases.

Sourcing 10-Propargyl-10-deazaaminopterin:

For pharmaceutical companies and research institutions looking to buy Pralatrexate or 10-Propargyl-10-deazaaminopterin, sourcing from reliable manufacturers is paramount. Key considerations when procuring this chemical include:

  • Purity Standards: Ensure the material meets high purity requirements (e.g., ≥98%) as specified for pharmaceutical intermediates.
  • Supplier Reliability: Choose manufacturers with a proven history of producing consistent quality products and a stable supply chain. We, as a China-based manufacturer, offer both reliability and competitive pricing.
  • Technical Documentation: Access to Certificates of Analysis (CoA) and Safety Data Sheets (SDS) is essential for quality assurance and safe handling.
  • Bulk Purchase Options: Inquire about pricing and availability for bulk quantities to support large-scale production needs.

As a dedicated manufacturer and supplier of 10-Propargyl-10-deazaaminopterin, we are committed to supporting the pharmaceutical industry with high-quality chemical intermediates. Understanding the intricate details of Pralatrexate's mechanism and therapeutic potential underscores its importance as a critical component in advanced cancer treatments.